CagriSema achieves significant weight loss in diabetes patients

hcplive.com

CagriSema has shown nearly 16% weight loss in adults with obesity and type 2 diabetes in the Phase 3 REDEFINE 2 trial, surpassing placebo results. Lorundrostat has demonstrated significant blood pressure reduction in patients with uncontrolled hypertension in recent Phase 3 and Phase 2 trials, maintaining a favorable safety profile. The FDA has set a new Priority Review date of June 4, 2025, for PharmaTher's ketamine treatment. Additionally, ATSN-201 gene therapy received Fast Track designation for X-linked retinoschisis, and the FDA approved the first interchangeable biosimilar for omalizumab.


With a significance score of 3, this news ranks in the top 22% of today's 18434 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 9000 minimalists.


loading...